Centre for Bioactive Molecules and Drug Delivery

June 2, 2017 Centre for Bioactive Molecules and Drug Delivery

Overview

The Centre for Bioactive Molecules and Drug Delivery (BMDD) consists of experts from diverse disciplines. The main aim of BMDD is to facilitate and to support a continuum of research and development activities from discovery and characterisation of bioactive molecules to clinical trials. Opportunities for commercialisation will be supported by the Commecialisation and Business Development Unit. BMDD consists of pharmaceutical chemists, life scientists, pharmaceutical technologists, pharmacists and medical experts. 

The expertise in chemistry includes organic and inorganic chemistry as well as analytical and synthetic chemistry. These experts are capable of performing in silico drug design and discovery and to synthesise small lead molecules. Our pharmaceutical chemists and technologists are adept in innovative drug formulation, employing the latest techniques in nanotechnology. They are also experienced in designing drugs with improved and superior delivery capabilities. Our main goals include the consolidation of all bioactive molecules into an electronic database as well as to set up a library of compounds. The purpose of the database and library is to facilitate research collaboration with our partner universities as well as external institutions through sharing of resources and expertise.

Purpose

To support the researchers and industry by providing the workable solutions in the following areas:

  • Preparation and development pharmaceutical formulations & cosmetics
  • Drug stability studies in pharmaceutical formulations & cosmetics
  • Development and validation of analytical methods
  • Trace element analysis in Pharmaceutical formulations, cosmetics, food products & environmental samples
  • Method development & validation for preparing the bioactive-enriched extracts
  • Design & synthesis of organic compounds and polymers
  • Prediction of the bioactivity and mechanisms of organic compounds using computational drug discovery and artificial intelligence technologies
  • In vitro & in vivo pharmacokinetics and metabolic stability studies
  • In vitro bioassays for determining the bioactivity and mechanism of bioactive compounds in metabolic, inflammatory, neurological & infectious diseases, and cancer
  • In vivo assays for determining the efficacy, potency, and safety of the bioactive compounds in experimental animal models for metabolic, inflammatory, neurological & infectious diseases, and cancer

Core Facilities

  • Drug discovery software
  • Formulation development
  • Analytical instrumentation
  • Animal house
  • Molecular mechanisms
  • Microwave synthesiser
  • Flash pressure liquid chromatography system

Strategic Plan

  • Increase the awareness of the researchers regarding the ‘Nanoverify’ programme.
  • Encourage the researchers to obtain the ‘Nanoverify’ certificate for their ‘nano products’
  • Encourage the researchers to develop herbal cosmetic formulations.
  • Develop analytical methods for the analysis of active pharmaceutical ingredients in the formulations.
  • Develop analytical methods for the analysis of nutritents in the formulations.
  • Provide consultancy services on integrated AI-CADD technologies in drug discovery
  • Provide consultancy services on developing formulations.
  • Provide consultancy services on extraction and characterisation of phytoconstituents.
  • Research on projects identified by CAPS for commercialisation
  • Workshops/CPDs in collaboration with IMU schools

Expertise / Team

Centre Head

Prof Dr Pichika Mallikarjuna Rao
Professor, Department of Pharmaceutical Chemistry, School of Pharmacy


 

Graduate Research Assistant

  • Ng Xiao Ying (GRA)
  • Samantha Yeoh Soo Ghee (GRA)
  • Nurul Shuhada binti M Yusri (GRA)